Does Finasteride Alter the Pathology of the Prostate and Cancer Grading?
Clinical Prostate Cancer · 2004-03 · 2 (4) · 228-235
DOI: 10.3816/cgc.2004.n.004 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Prostate Cancer, 2004-03. Verfasst von David G Bostwick und 4 weiteren Autor:innen. Beteiligte Einrichtung: Bostwick Laboratories, Richmond, VA 23294, USA. bostwick@bostwicklaboratories.com. Hauptthemen laut MEDLINE: 5-alpha Reductase Inhibitors. Die Arbeit wurde bisher 70-mal zitiert (Crossref) und nennt 94 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Bostwick Laboratories, Richmond, VA 23294, USA. bostwick@bostwicklaboratories.com
Zitieren
APA
Bostwick, D. G., Qian, J., Civantos, F., Roehrborn, C. G., & Montironi, R. (2004). Does Finasteride Alter the Pathology of the Prostate and Cancer Grading?. Clinical Prostate Cancer, 2(4), 228-235. https://doi.org/10.3816/cgc.2004.n.004
Vancouver
Bostwick DG, Qian J, Civantos F, Roehrborn CG, Montironi R. Does Finasteride Alter the Pathology of the Prostate and Cancer Grading?. Clinical Prostate Cancer. 2004;2(4):228-235. doi:10.3816/cgc.2004.n.004
BibTeX
@article{Bostwick2004,
author = {Bostwick, David G and Qian, Junqi and Civantos, Francisco and Roehrborn, Claus G and Montironi, Rodolfo},
title = {Does Finasteride Alter the Pathology of the Prostate and Cancer Grading?},
journal = {Clinical Prostate Cancer},
year = {2004},
volume = {2},
number = {4},
pages = {228--235},
doi = {10.3816/cgc.2004.n.004}
}
EUVIMED